Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE


Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).

Aim(s): To describe baseline quality of life and tumour characteristics of patients in CLARINET FORTE (NCT02651987), a phase 2 study of LAN 120 mg q14 days in progressive pancreatic NETs (panNETs) and midgut NETs.

Materials and methods: Equal recruitment of patients with panNETs and midgut NETs, with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≤2 (0: normal; 1: restricted activity; 2: ≤50% of time in bed), and a well differentiated, metastatic or locally advanced, WHO Grade G1/G2 NET with a proliferation index ≤20% and centrally assessed radiological progression on a standard LAN regimen within the last 2 years, was planned. All patients received LAN 120 mg q14 days.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Neuroendocrine tumours, lanreotide,

To read the full abstract, please log into your ENETS Member account.